NDC 61990-0120-1 - PIPERACILLIN AND TAZOBACTAM
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 61990-0120
- Requested NDC
- 61990-0120-1
- Package NDCs from labels
- 61990-0120-1, 61990-0120-2
- Manufacturer
- Apollo Pharmaceuticals Inc.
- Effective date
- 2023-03-24
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| PIPERACILLIN AND TAZOBACTAM - Apollo Pharmaceuticals Inc. | Apollo Pharmaceuticals Inc. | 2023-03-24 | HUMAN PRESCRIPTION DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 61990-0120-1 | EA - Each | 61990-0120 | 64d81feb-b6dd-41bc-afe9-7caa39ab9e89 | 1 | 2019-08-06 |
| 61990-0120-2 | EA - Each | 61990-0120 | 7240d4ba-c636-4e45-8da8-d15584ae5856 | 1 | 2019-08-06 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Zosyn | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Baxter Healthcare Corporation | 8db6bd91-2106-4bfd-8cc8-38aaf1e18d17 | 2026-05-15 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| ZERBAXA | CEFTOLOZANE AND TAZOBACTAM | Merck Sharp & Dohme LLC | 70ac1d90-eff3-4f0b-9f46-5846c571b32f | 2026-05-12 | Warnings, Adverse reactions | UXA545ABTT |
| Piperacillin and Tazobactam and Sodium Chloride | PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE | B. Braun Medical Inc. | a63ca653-27d4-45fe-a744-77e0efe45220 | 2026-05-08 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Civica, Inc. | 19e89f8b-316b-4dd2-9724-bfe0faeba408 | 2025-12-12 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM,TAZOBACTAM SODIUM | WG Critical Care, LLC | 2cd82553-79dc-45f0-9755-2c08df524ed5 | 2025-10-31 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| piperacillin and tazobactam | PIPERACILLIN AND TAZOBACTAM | Civica, Inc. | 7aebc0e6-89db-4ef0-b5ab-d6b3199bcfc4 | 2025-09-08 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Avenacy, LLC | 668a2730-e95a-4639-a506-ae95a6502ca1 | 2025-09-01 | Boxed warning, Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Eugia US LLC | 39e19789-de4b-4fd1-ab1c-92f59496f496 | 2025-08-19 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Eugia US LLC | a5d8625e-e630-4076-bc55-46ebe861c6a5 | 2025-08-08 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| piperacillin and tazobactam | PIPERACILLIN AND TAZOBACTAM | ONESOURCE SPECIALTY PHARMA LIMITED | 28258745-12e4-4f0f-b318-4a1a1bebc928 | 2025-07-21 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Avenacy, LLC | 9114cea1-3338-487e-87fa-cc3a409d501a | 2025-07-07 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | BluePoint Laboratories | 1aba753c-d0c2-4b35-917a-9143dd4be468 | 2025-06-20 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Apotex Corp. | 2c8f06a2-49b2-4169-94ef-182d13d248bf | 2025-05-21 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Fresenius Kabi USA, LLC | c5cddf50-e486-4ffb-9bc6-ed67ad6bc154 | 2025-04-14 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Fresenius Kabi USA, LLC | a798faf5-cd97-4e35-a700-94c372978c46 | 2025-04-14 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Fresenius Kabi USA, LLC | 6a894b94-171f-4217-81a2-0e84796b0b41 | 2025-04-11 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Fresenius Kabi USA, LLC | c8e3cc43-238d-4a23-95dc-157c85f83184 | 2025-04-10 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Provepharm Inc. | 68d5384d-1691-4afc-8a1a-488f8e2ef2c5 | 2025-02-26 | Boxed warning, Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| PIPERACILLIN AND TAZOBACTAM | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Provepharm Inc. | bc26ffd8-1a6e-4e16-91c1-ec67c928b3bf | 2025-02-26 | Warnings, Adverse reactions | ANDA207847 M98T69Q7HP UXA545ABTT |
| 266a53a2-c142-067c-e063-6394a90ab4b0 | 8eed2d4d-f40b-02bb-e053-2a95a90a880f | 2024-11-08 | Warnings, Adverse reactions | 8eed2d4d-f40b-02bb-e053-2a95a90a880f |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.